Nova Bio News Today

A forward referendums on joining russia currently being held in the don boston to ukrainian regions in our special coverage International Observer shaved their assessment from the voting. Everything should be done legally. I so that is exactly the same, like in, in rush hour in france. What we saw there was, according to the normal standards of elections. Ah, hello and welcome to our international. Were coming to you for my headquarters here in moscow. Im policy clear, and its a pleasure to be w...

Investors consistently seek out factors that could influence price fluctuations. A significant catalyst that frequently exerts a profound influence on prices is news. Favorable news possesses the...

Protection of T cells from tumor-induced suppression suggests potential for enhancing efficacy of therapies, with plans to initiate a phase 1/2 clinical trial in patients with advanced breast cancer.

Company Receives Institutional Review Board Approval for 10 Patient Proof of Concept Oncology TrialELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today plans to initiate ten patient proof-of-concept clinical trial aimed at demonstrating the ability of FloraStilbene™ to stimula...

Published: Dec 10, 2020   NEW YORK, Dec. 10, 2020 /PRNewswire/ -- PhageNova Bio, Inc. ("PhageNova") is pleased to announce the publication of data generated through a sponsored research agreement with Rutgers, The State University of New Jersey. The Med (a Cell Press publication) article, entitled Targeted Phage Display-Based Pulmonary Vaccination in Mice and Non-human Primates, describes a new method for safe and effective pulmonary delivery of therapeutics, including an aerosol vacci...